EP3021945A4 - Compositions and methods of detecting and treating neural tube defects - Google Patents

Compositions and methods of detecting and treating neural tube defects Download PDF

Info

Publication number
EP3021945A4
EP3021945A4 EP14826462.5A EP14826462A EP3021945A4 EP 3021945 A4 EP3021945 A4 EP 3021945A4 EP 14826462 A EP14826462 A EP 14826462A EP 3021945 A4 EP3021945 A4 EP 3021945A4
Authority
EP
European Patent Office
Prior art keywords
compositions
detecting
methods
neural tube
tube defects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14826462.5A
Other languages
German (de)
French (fr)
Other versions
EP3021945A1 (en
Inventor
C. Shekhar Mayanil
Elise ALLENDER
Takao TSURUBUCHI
Norman GINSBERG
David G. MCLONE
Tadanori Tomita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ann and Robert H Lurie Childrens Hospital of Chicago
Original Assignee
Ann and Robert H Lurie Childrens Hospital of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ann and Robert H Lurie Childrens Hospital of Chicago filed Critical Ann and Robert H Lurie Childrens Hospital of Chicago
Publication of EP3021945A1 publication Critical patent/EP3021945A1/en
Publication of EP3021945A4 publication Critical patent/EP3021945A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
EP14826462.5A 2013-07-18 2014-07-15 Compositions and methods of detecting and treating neural tube defects Withdrawn EP3021945A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361847662P 2013-07-18 2013-07-18
PCT/US2014/046673 WO2015009710A1 (en) 2013-07-18 2014-07-15 Compositions and methods of detecting and treating neural tube defects

Publications (2)

Publication Number Publication Date
EP3021945A1 EP3021945A1 (en) 2016-05-25
EP3021945A4 true EP3021945A4 (en) 2017-06-07

Family

ID=52344048

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14826462.5A Withdrawn EP3021945A4 (en) 2013-07-18 2014-07-15 Compositions and methods of detecting and treating neural tube defects

Country Status (4)

Country Link
US (1) US20150025008A1 (en)
EP (1) EP3021945A4 (en)
JP (1) JP2016530243A (en)
WO (1) WO2015009710A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943549B2 (en) * 2015-03-17 2018-04-17 Food Industry Research And Development Institute Isolation of human neural stem cells from amniotic fluid of patients with neural tube defects
CN109988829B (en) * 2019-03-08 2022-08-23 首都儿科研究所 Molecular marker for detecting neural tube deformity and application thereof
CN111721932B (en) * 2019-03-20 2024-08-16 复旦大学 Screening method of small molecular compound taking CD133 as target spot and application of small molecular compound in pharmacy
CN115326953A (en) * 2022-08-02 2022-11-11 云谱康(大连)生物科技有限公司 Metabolite combination and application, detection kit and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
US20120100113A1 (en) * 2010-10-26 2012-04-26 Case Western Reserve University Differentiation method for production of glial cell populations
WO2013006372A1 (en) * 2011-07-01 2013-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating pathologic heterotopic ossification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
WO2007028212A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
US7723301B2 (en) * 2007-08-29 2010-05-25 The Board Of Trustees Of The University Of Arkansas Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
KR20110059755A (en) * 2008-09-19 2011-06-03 메디뮨 엘엘씨 Antibodies against sonic hedgehog homolog and uses thereof
FR2980477B1 (en) * 2011-09-23 2013-10-18 Centre Nat Rech Scient NOVEL MODULATING COMPOUNDS OF THE HEDGEHOG PROTEIN SIGNALING PATH, THEIR MARKED FORMS, AND APPLICATIONS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
US20120100113A1 (en) * 2010-10-26 2012-04-26 Case Western Reserve University Differentiation method for production of glial cell populations
WO2013006372A1 (en) * 2011-07-01 2013-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating pathologic heterotopic ossification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015009710A1 *
STOTTMANN R W ET AL: "The BMP antagonist Noggin promotes cranial and spinal neurulation by distinct mechanisms", DEVELOPMENTAL BIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 295, no. 2, 15 July 2006 (2006-07-15), pages 647 - 663, XP024943876, ISSN: 0012-1606, [retrieved on 20060715], DOI: 10.1016/J.YDBIO.2006.03.051 *

Also Published As

Publication number Publication date
US20150025008A1 (en) 2015-01-22
EP3021945A1 (en) 2016-05-25
JP2016530243A (en) 2016-09-29
WO2015009710A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
HK1225654A1 (en) Compositions and methods for the treatment of presbyopia
HK1217908A1 (en) Methods of treating cholangiocarcinoma
EP3245225A4 (en) Compositions and methods for treatment and detection of cancers
EP3094352A4 (en) Compositions and methods for treatment and detection of cancers
EP2961441A4 (en) Method and apparatus for optical detection of bio-contaminants
EP3013957A4 (en) Compositions and methods for sample processing
EP3011308A4 (en) Scratch testing apparatus and methods of using same
EP3075001A4 (en) Detectors and methods of using them
GB201315196D0 (en) Apparatus and method for determining the mechanical properties of cells
EP3038646A4 (en) Diagnostic methods and compositions for treatment of glioblastoma
GB201319105D0 (en) Detection apparatus and method
GB201320723D0 (en) Composition and methods of treatment
EP2993460A4 (en) Target-substance detection apparatus and method
EP3084000A4 (en) Method of diagnosis and treatment
EP2967429A4 (en) Methods and apparatus for enhanced detection of diseases
GB2513304B (en) Peripheral apparatus and method of construction
EP3066472A4 (en) Compositions and methods for detecting and/or treating inflammation
SG11201510243QA (en) Method of control of persons and application to the inspection of persons
IL243570B (en) Compositions and kits for the treatment of atopic dermatitis
IL232696A0 (en) Composition and method for detection of molecules of interest
EP2975416A4 (en) Measuring apparatus and measuring method
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
EP3063520B8 (en) Detection apparatus and method
EP3065691A4 (en) Apparatus and methods of use
EP3071240A4 (en) Methods and compositions for treating amyloid deposits

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TSURUBUCHI, TAKAO

Inventor name: MAYANIL, C. SHEKHAR

Inventor name: TOMITA, TADANORI

Inventor name: ALLENDER, ELISE

Inventor name: GINSBERG, NORMAN

Inventor name: MCLONE, DAVID G.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170511

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101AFI20170504BHEP

Ipc: C12N 5/073 20100101ALI20170504BHEP

Ipc: A61K 38/18 20060101ALI20170504BHEP

Ipc: A61K 31/519 20060101ALI20170504BHEP

Ipc: A61K 31/4418 20060101ALI20170504BHEP

Ipc: C12N 5/0775 20100101ALI20170504BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171212